Pracinostat - CAS 929016-96-6
Catalog number: B0084-286706
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C20H30N4O2
Molecular Weight:
358.486
COA:
Inquire
Targets:
HDAC
Description:
Pracinostat (SB939) is an orally bioavailable, small-molecule histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Pracinostat inhibits HDACs, which may result in the accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; the tumor suppressor protein-mediated inhibition of tumor cell division; and, finally, the induction of tumor cell apoptosis. This agent may possess improved metabolic, pharmacokinetic and pharmacological properties compared to other HDAC inhibitors.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-286706 1 g $1298 In stock
B0084-286706 5 g $3200 In stock
Bulk Inquiry
Purity:
>98%
Appearance:
white solid powder
Synonyms:
SB939; SB 939; SB-939; SC-939; SC 939; SC939; Pracinostat.
MSDS:
Inquire
InChIKey:
JHDKZFFAIZKUCU-ZRDIBKRKSA-N
InChI:
InChI=1S/C20H30N4O2/c1-4-7-8-19-21-17-15-16(10-12-20(25)22-26)9-11-18(17)24(19)14-13-23(5-2)6-3/h9-12,15,26H,4-8,13-14H2,1-3H3,(H,22,25)/b12-10+
Canonical SMILES:
CCCCC1=NC2=C(N1CCN(CC)CC)C=CC(=C2)C=CC(=O)NO
Current Developer:
S*Bio.
1.The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML.
Novotny-Diermayr V1, Hart S, Goh KC, Cheong A, Ong LC, Hentze H, Pasha MK, Jayaraman R, Ethirajulu K, Wood JM. Blood Cancer J. 2012 May;2(5):e69. doi: 10.1038/bcj.2012.14. Epub 2012 May 4.
Acute myeloid leukemia (AML) is currently treated with aggressive chemotherapy that is not well tolerated in many elderly patients, hence the unmet medical need for effective therapies with less toxicity and better tolerability. Inhibitors of FMS-like tyrosine kinase 3 (FLT3), JAK2 and histone deacetylase inhibitors (HDACi) have been tested in clinical studies, but showed only moderate single-agent activity. High efficacy of the HDACi pracinostat treating AML and synergy with the JAK2/FLT3 inhibitor pacritinib is demonstrated. Both compounds inhibit JAK-signal transducer and activator of transcription (STAT) signaling in AML cells with JAK2(V617F) mutations, but also diminish FLT3 signaling, particularly in FLT3-ITD (internal tandem duplication) cell lines. In vitro, this combination led to decreased cell proliferation and increased apoptosis. The synergy translated in vivo in two different AML models, the SET-2 megakaryoblastic AML mouse model carrying a JAK2(V617F) mutation, and the MOLM-13 model of FLT3-ITD-driven AML.
2.Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis.
Quintás-Cardama A1, Kantarjian H, Estrov Z, Borthakur G, Cortes J, Verstovsek S. Leuk Res. 2012 Sep;36(9):1124-7. doi: 10.1016/j.leukres.2012.03.003. Epub 2012 Apr 2.
Approximately half of the patients with myelofibrosis (MF) carry mutant JAK2(V617F) proteins. JAK2(V617F) has been recently shown to translocate to the nucleus and modify specific histones, thus regulating transcription. We report on a phase II study testing the activity and tolerability of the histone deacetylase inhibitor pracinostat given at 60 mg every other day for three weeks per month in 22 patients with intermediate or high risk MF. Eight (36%) patients experienced clinical benefit, with 6 (27%) experiencing reductions in splenomegaly (median 3 cm, range 1-4 cm). According to International Working Group criteria, 2 (9%) patients had clinical improvement (anemia response in both cases). The most frequent side effect associated to pracinostat therapy was fatigue, which occurred in 20 (91%) patients (grade 2 in 3 patients). Grade 3-4 neutropenia, anemia, and thrombocytopenia occurred in 13%, 0%, and 21%, respectively. Twenty-one patients permanently discontinued pracinostat, mainly due to lack of efficacy.
3.Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.
Ganai SA1. Pharm Biol. 2016 Feb 5:1-10. [Epub ahead of print]
Context Histone deacetylase inhibitors (HDACi) have shown promising results in neurodegeneration and cancer. Hydroxamate HDACi, including vorinostat, have shown encouraging results in haematological malignancies, but the poor pharmacokinetic of these inhibitors leads to insufficient tumour concentration limiting their application against solid malignancies. Objective This article deals with novel HDAC inhibitor pracinostat (SB939) and delineates its therapeutic role in solid and haematological malignancies. The article provides rigorous details about the underlying molecular mechanisms modulated by pracinostat to exert cytotoxic effect. The article further highlights the doublet therapy that may be used to tackle monotonous cancer chemoresistance. Methods Both old and the latest literature on pracinostat was retrieved from diverse sources, such as PubMed, Science Direct, Springer Link, general Google search using both pracinostat and SB939 keywords in various ways: after thorough evaluation the topic which can fulfil the current gap was chosen.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related HDAC Products


CAS 848354-66-5 PTACH

PTACH
(CAS: 848354-66-5)

PTACH is a SAHA-based novel inhibitor of histone deacetylase (HDAC). It exerts potent growth inhibition against various human cancer cells, with EC50 values ran...

CAS 1236199-60-2 EDO-S101

EDO-S101
(CAS: 1236199-60-2)

EDO-S101 is a pan HDAC inhibitor (IC50= 9, 9 and 25 nM for HDAC1, HDAC2 and HDAC3, respectively). EDO-S101 is a first-in-class fusion molecule that combines DNA...

CAS 1375465-91-0 ACY-738

ACY-738
(CAS: 1375465-91-0)

ACY-738 is a potent and selective HDAC6 inhibitor with improved brain bioavailability. ACY-738 inhibits HDAC6 with low nanomolar potency and a selectivity of 60...

CAS 1440209-96-0 BRD73954

BRD73954
(CAS: 1440209-96-0)

BRD73954 ia a potent and selective HDAC inhibitor with IC50 of 36 nM and 120 nM for HDAC6 and HDAC8, respectively.

GSK3117391
(CAS: 1018673-42-1)

GSK3117391, a HDAC inhibitor, was developed by GSK considering its potential effect in the treatment of arthritis and rheumatoid. It was already being terminate...

CAS 1186222-89-8 4SC-202

4SC-202
(CAS: 1186222-89-8)

4SC-202 is an orally bioavailable benzamide and inhibitor of human class I histone deacetylases (HDACs) isoenzymes 1, 2 and 3, with potential antineoplastic act...

HDAC-IN-1
(CAS: 1239610-44-6)

HDAC-IN-1, an analogue of MC 1568, is a Iia HDACs inhibitor that could probably influence myogenesis and adipogenesis.

CAS 1316214-52-4 Rocilinostat

Rocilinostat
(CAS: 1316214-52-4)

Rocilinostat is an orally bioavailable histone deacetylase 6 (HDAC6) inhibitor with potential antineoplastic activity. It selectively targets and binds to HDAC6...

Chemical Structure

CAS 929016-96-6 Pracinostat

Quick Inquiry

Verification code

Featured Items